Abstract
The amyloid-β (Aβ) peptide is the principal components of the senile plaques found in the brains of patients with Alzheimers disease (AD). The poorly soluble 40-42 amino acid peptide, formed from the cleavage of the Ab precursor protein (APP) by two proteases, is believed to play a central role in the pathogenesis of AD. β-Secretase (memapsin 2, BACE1), a membrane-anchored aspartic protease, is responsible for the initial step of APP cleavage leading to the generation of Aβ. Identification and structural determination of β-secretase have established it to be a primary drug target for AD therapy and stimulated active studies on the inhibitors of this protease. Here we review more recent developments in the design and testing of structure-based β-secretase inhibitors.
Keywords: Alzheimer's disease, amyloid-β peptide, β-amyloid precursor protein, β-Secretase, Memapsin 2, aspartyl protease inhibitors, BACE-1, neurodegenerative disease, drug development
Current Topics in Medicinal Chemistry
Title: Recent Developments of Structure Based β-Secretase Inhibitors for Alzheimers Disease
Volume: 5 Issue: 16
Author(s): Aurn K. Ghosh, Nagaswamy Kumaragurubaran and Jordan Tang
Affiliation:
Keywords: Alzheimer's disease, amyloid-β peptide, β-amyloid precursor protein, β-Secretase, Memapsin 2, aspartyl protease inhibitors, BACE-1, neurodegenerative disease, drug development
Abstract: The amyloid-β (Aβ) peptide is the principal components of the senile plaques found in the brains of patients with Alzheimers disease (AD). The poorly soluble 40-42 amino acid peptide, formed from the cleavage of the Ab precursor protein (APP) by two proteases, is believed to play a central role in the pathogenesis of AD. β-Secretase (memapsin 2, BACE1), a membrane-anchored aspartic protease, is responsible for the initial step of APP cleavage leading to the generation of Aβ. Identification and structural determination of β-secretase have established it to be a primary drug target for AD therapy and stimulated active studies on the inhibitors of this protease. Here we review more recent developments in the design and testing of structure-based β-secretase inhibitors.
Export Options
About this article
Cite this article as:
Ghosh K. Aurn, Kumaragurubaran Nagaswamy and Tang Jordan, Recent Developments of Structure Based β-Secretase Inhibitors for Alzheimers Disease, Current Topics in Medicinal Chemistry 2005; 5 (16) . https://dx.doi.org/10.2174/156802605775009711
DOI https://dx.doi.org/10.2174/156802605775009711 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Updates of Chemically Modified Electrodes in Pharmaceutical Analysis
Combinatorial Chemistry & High Throughput Screening Development and Validation of HPLC Methods for the Determination of CYP2D6 and CYP3A4 Activities
Current Pharmaceutical Analysis Self-inflicted Bilateral Ocular Perforation in an Adolescent Patient with Major Depressive Disorder and Borderline Personality Traits
Adolescent Psychiatry Novel Nucleic Acid-Based Agents: siRNAs and miRNAs
Central Nervous System Agents in Medicinal Chemistry The Many Faces of Tourette Syndrome
Current Drug Therapy Vitiligo: An Updated Narrative Review
Current Pediatric Reviews Inhibition of Monoamine Neurotransmitter Transporters and Central Nervous System Stimulation Induced by Synthetic Local Anesthetics and Cocaine: A Comparative Review-Update
Current Medicinal Chemistry - Central Nervous System Agents Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology Genetic Susceptibility to Autoimmune Disorders: Clues from Gene Association and Gene Expression Studies
Current Molecular Medicine “Ride or Die”: Therapeutic Interventions for Retaliatory Violence Among Youth
Adolescent Psychiatry Diversity of Molecular Factors in Alzheimer’s Disease
Current Alzheimer Research Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets From the Editors Perspective: Activity, Anoxia, Angiogenesis, and Alzheimers Disease
Current Neurovascular Research Purinergic Signaling and Energy Homeostasis in Psychiatric Disorders
Current Molecular Medicine Neurological Aspects of Medical Use of Cannabidiol
CNS & Neurological Disorders - Drug Targets Benefit of 13-desmethyl Spirolide C Treatment in Triple Transgenic Mouse Model of Alzheimer Disease: Beta-Amyloid and Neuronal Markers Improvement
Current Alzheimer Research Hip but Not Thigh Intramuscular Adipose Tissue is Associated with Poor Balance and Increased Temporal Gait Variability in Older Adults
Current Aging Science The Contribution of Nitric Oxide and Carbon Monoxide to Neuronal Function and Development
Central Nervous System Agents in Medicinal Chemistry TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Updates on Therapeutics in Clinical Trials for Spinal Cord Injuries: Key Translational Applications of Human Embryonic Stem Cells-Derived Neural Progenitors
CNS & Neurological Disorders - Drug Targets